drives and wiped out e-mails. the report has resulted in a legal back and forth that now involves the dnc. i m talk with one of the reporters who broke that big political story. today the fda revoked the drus of astin as a drug for breast cancer saying the drus exposes patients to serious side effects like high blood pressure and hemorrhaging with no proven benefits. we have the chief of the american society of clinical oncologists. thank you very much for joining us. we know you have a deep understanding of this. why did the fda make this decision? because we are already hearing of course from patients with met static breast cancer who say that benefits outweigh the risks. sure. so that s exactly what the fda is weighing when they make a decision about initial approval of a drug, and then when they re-evaluate new kefd that s come online with regard to whether the drug should remain on the market.